Dose-response study of 22-oxacalcitriol in patients with secondary hyperparathyroidism
Dose-response study of 22-oxacalcitriol in patients with secondary hyperparathyroidism
复制标题
DOI：
10.1111/j.1774-9987.2004.00191.x
复制
发表时间：
2004-12-01
影响因子：
1.9
通讯作者：
Kurokawa, K
中科院分区：
文献类型：
--
作者：
Akizawa, T;Ohashi, Y;Kurokawa, K
通过双盲平行组设计评估了每周三次定期血液透析（HD）的继发性甲状旁腺功能亢进症（2HPT）患者服用22-奥沙骨化三醇（OCT）的剂量反应关系和安全性。总共 203 例 2HPT 患者被随机分为 4 组，每次 HD 结束时给予 5 杯（L 组）、10 杯（M 组）或 15 杯（H 组）OCT 或安慰剂（P 组），持续 12 周。治疗 12 周后，P 组中 7.7% 的人观察到完整甲状旁腺激素 (iPTH) 浓度较基线降低超过 30%，而 OCT 合并组中这一比例为 77.3%（Mantel 检验：P
The dose-response relationships and the safety of administering 22-oxacalcitriol (OCT) to patients with secondary hyperparathyroidism (2HPT) under regular three-times-weekly hemodialysis (HD) were evaluated by double-blind parallel group design. A total of 203 patients with 2HPT were randomly allocated into four groups, and 5 mug (Group L), 10 mug (Group M), or 15 mug (Group H) OCT, or placebo (Group P) was administrated at the end of every HD for 12 weeks. Reductions of intact-parathyroid hormone (iPTH) concentration greater than 30% from baseline were observed in 7.7% of Group P as compared to 77.3% of the pooled OCT groups after 12 weeks of treatment (Mantel test: P